Mepolizumab for severe eosinophilic asthma: a real-world snapshot on clinical markers and timing of response

References

• To T, Stanojevic S, Moores G, et al. Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health. 2012;19(12):204.
   Google Scholar
• Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43:343–373.
   PubMed Web of Science ®Google Scholar
• Humbert M, Busse W, Hanania NA, et al. Omalizumab in asthma: an update on recent developments. J Allergy Clin Immunol Pract. 2014;2:525–536.
   PubMed Web of Science ®Google Scholar
• Bagnasco D, Caminati M, Ferrando M, et al. Anti-IL-5 and IL-5Ra: efficacy and safety of new therapeutic strategies in severe uncontrolled asthma. Biomed Res Int. 2018 Nov 5;2018:5698212.
   PubMed Web of Science ®Google Scholar
• Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009;360:973–984.
   PubMed Web of Science ®Google Scholar
• Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med. 2009 Mar;5(360):985–993.
   Google Scholar
• Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380:651–659.
   PubMed Web of Science ®Google Scholar
• Ortega HG, Liu MC, Pavord ID, et al. MENSA investigators. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371:1198–1207.
   PubMed Web of Science ®Google Scholar
• Bel EH, Wenzel SE, Thompson PJ, et al. SIRIUS investigators. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371:1189–1197.
   PubMed Web of Science ®Google Scholar
• Lugogo N, Domingo C, Chanez P, et al. Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study. Clin Ther. 2016 Sep;38(9):2058–2070.e1.
   PubMed Web of Science ®Google Scholar
• Chupp GL, Bradford ES, Albers FC, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017 May;5(5):390–400.
   PubMed Web of Science ®Google Scholar
• Khatri S, Moore W, Gibson PG, et al. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J Allergy Clin Immunol. 2018 Oct 23;S0091–6749(18):1742–1751.e7.
   Google Scholar
• Saturni S, Bellini F, Braido F, et al. Randomized controlled trials and real life studies. Approaches and methodologies: a clinical point of view. Pulm Pharmacol Ther. 2014;27:129–138.
   PubMed Web of Science ®Google Scholar
• Caminati M, Senna G, Guerriero M, et al. Omalizumab for severe allergic asthma in clinical trials and real-life studies: what we know and what we should address. Pulm Pharmacol Ther. 2015;31:28–35.
   PubMed Web of Science ®Google Scholar
• Caminati M, Senna G, Chieco Bianchi F, et al. NEONET study group. Omalizumab management beyond clinical trials: the added value of a network model. Pulm Pharmacol Ther. 2014;29:74–79.
   PubMed Web of Science ®Google Scholar
• Mepolizumab EPAR. [ cited 2019 Feb 20]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/nucala
   Google Scholar
• Bagnasco D, Milanese M, Rolla G, et al. The North-Western Italian experience with anti IL-5 therapy and comparison with regulatory trials. World Allergy Organ J. 2018 Dec 6;11(1):34.
   PubMedGoogle Scholar
• Pelaia C, Busceti MT, Solina S, et al. Real life of the clinical, functional and hematologic effects of mepolizumab in patients with severe eosinophilic asthma: results of a single-centre observational study. Pulm Pharmacol Ther. 2018;53:1–5.
   PubMed Web of Science ®Google Scholar
• Drick N, Seeliger B, Welte T, et al. Anti-IL-5 therapy in patients with severe eosinophilic asthma – clinical efficacy and possible criteria for treatment response. BMC Pulm Med. 2018;18:119.
   PubMed Web of Science ®Google Scholar
• Kurosawa M, Sutoh E. Prospective open-label study of 48-week subcutaneous administration of mepolizumab in Japanese patients with severe eosinophilic asthma. J Investig Allergol Clin Immunol. 2019;29(1):40–45.
   PubMed Web of Science ®Google Scholar
• Ojanguren I, Chaboillez S, Lemiere C. Low blood eosinophil counts are not always a reliable marker of clinical response to mepolizu- mab in severe asthma. J Allergy Clin Immunol Pract. 2018;30:S2213–S2198.
   Google Scholar
• Caminati M, Vianello A, Chieco Bianchi F, et al. NEONET study group. Relevance of Th2 markers in the assessment and therapeutic management of severe allergic asthma: a real life perspective. J Investig Allergol Clin Immunol. 2019 Jan 24:1–22.
   PubMedGoogle Scholar
• Caminati M, Senna G. Uncontrolled severe asthma: starting from the unmet needs. Curr Med Res Opin. 2018 Oct;29:1–3.
   Google Scholar
• Pavlidis S, Takahashi K, Ng Kee Kwong F, et al. “T2-high” in severe asthma related to blood eosinophil, exhaled nitric oxide and serum periostin. on behalf of the U-BIOPRED study group. Eur Respir J. 2019 Jan 3;53(1):pii: 1800938.
   PubMed Web of Science ®Google Scholar
• Hoyte FCL, Gross LM, Katial RK. Exhaled nitric oxide: an update. Immunol Allergy Clin North Am. 2018 Nov;38(4):573–585.
   PubMed Web of Science ®Google Scholar
• Caminati M, Pham DL, Bagnasco D, et al. Type 2 immunity in asthma. World Allergy Organ J. 2018 Jun 26;11(1):13.
   PubMedGoogle Scholar
• Sullivan PW, Ghushchyan VH, Globe G, et al. Oral corticosteroid exposure and adverse effects in asthmatic patients. J Allergy Clin Immunol. 2018;141:110–116.e7.
   PubMed Web of Science ®Google Scholar
• Barry LE, O’Neill C, Patterson C, et al. Age and sex associations with systemic corticosteroid-induced morbidity in asthma. J Allergy Clin Immunol Pract. 2018 Nov- Dec;6(6):2014–2023.e2.
   PubMed Web of Science ®Google Scholar
• Vianello A, Caminati M, Andretta M, et al. Prevalence of severe asthma according to the drug regulatory agency perspective: an Italian experience. World Allergy Organ J. 2019 May 10;12(4):100032.
   PubMed Web of Science ®Google Scholar
• Italian regulatory agency dispositions about the use of nucala. [ cited 2019 Feb 20]. Available from: http://www.gazzettaufficiale.it/eli/id/2017/02/28/17A01570/sg;jsessionid=GDAhkFaCP3aDv1A99QwQ__.ntc-as2-guri2a
   Google Scholar